Navigation Links
Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
Date:6/16/2013

h the ABC-subtype of DLBCL are difficult to treat, these results are very promising."

About Ibrutinib
Ibrutinib was designed to specifically target and selectively inhibit an enzyme called BTK. BTK is a key mediator of at least three critical B-cell pro-survival mechanisms occurring in parallel — regulation of apoptosis, cell adhesion and cell migration and homing.

The effectiveness of ibrutinib alone or in combination with other treatments is being studied in several B-cell malignancies, including chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, Waldenstrom's macroglobulinemia and multiple myeloma. To date 7 Phase III trials have been initiated with ibrutinib and a total of 30 ongoing trials are currently registered on http://www.clinicaltrials.gov/. Janssen Biotech, Inc. and Pharmacyclics entered a collaboration and license agreement in December 2011 to co-develop and co-commercialize ibrutinib.

About the MCL Study
111 patients with relapsed/refractory MCL were treated with ibrutinib in this Phase 2 multicenter, open-label, study at 18 sites internationally and had received a median of three prior therapies. Patients were divided into two cohorts based on prior bortezomib exposure – either bortezomib-naive (n=63) or bortezomib-exposed (n=48). Both groups received 560 mg of ibrutinib orally, once a day until disease progression or no longer tolerated by the patient. The primary endpoint of the study was ORR, with secondary endpoints being DOR, PFS, OS and frequency and severity of AEs.

When a disease is described as 'relapsed', it means that it has returned after an initial partial or total remission.[1] 'Refractory' refers to cancer that has become resistant to current treatment.[2]

About the DLBCL Study
The DLBCL study was a Phase 2 multicenter, open-label,
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Hill-Rom Reports Fiscal Second Quarter Adjusted Earnings Per Share In Line With Expectations; Provides Third Quarter And Updated Full-Year Financial Outlook
2. Updated HHS Mandate Continues Attack on Religious Freedom
3. Hoggan Scientific Unveils Updated ergoFET Force Gauge for Improved Force Evaluation
4. Updated: LHA Life Sciences & Medical Technologies Virtual Conference
5. Syndax Pharmaceuticals to Present Updated Overall Survival Data With Entinostat in Metastatic Breast Cancer at ASCO
6. Ongoing Clinical Trials Reveal Groundbreaking Results - Research Report on Alexion, BioMarin, Onyx, Questcor, and ImmunoGen
7. NeuroDerm Announces Presentation of ND0612 Phase 1 and Phase 2 Results at the 2013 International Congress of Parkinsons Disease and Movement Disorders
8. New PrEP Trial Results Among Injecting Drug Users Underscore That PrEP Works When Taken Consistently
9. Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
10. Lakeland Industries to Report Fiscal First Quarter Financial Results and Conduct Conference Call
11. Adamas Pharmaceuticals To Report Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia In Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)...  MiMedx Group, Inc. (NASDAQ: MDXG ), ... tissue and patent-protected processes to develop and market ... Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental ... multiple inaccuracies in the press release issued by ... rulings from the Patent Trial and Appeal Board ...
(Date:8/27/2015)... the leading innovation partner to companies worldwide , ... and anticipates the creation of over 350 new jobs through ... In 2013, the State of Ohio ... to accelerate adoption of open innovation among Ohio ... revenues. To date over 45 middle market companies have worked ...
(Date:8/27/2015)... 27, 2015  Hill-Rom Holdings, Inc., (NYSE: HRC ... at the Morgan Stanley Global Healthcare Conference on September ... are invited to listen to the live discussion via ... directly at https://cc.talkpoint.com/morg007/091615a_ae/?entity=49_UCJPU8N . A recorded ... after the conclusion of the live event and accessible ...
Breaking Medicine Technology:MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 2MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 3MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 4State of Ohio and NineSigma Collaborate to Drive Regional Economic Growth and Job Creation 2State of Ohio and NineSigma Collaborate to Drive Regional Economic Growth and Job Creation 3
... N.J. , May 27 Tibotec Therapeutics, a ... launch of the HIV Case Manager Portal (the ... designed to help HIV/AIDS front-line service providers meet their daily ... in Denver, CO at the 22nd National Conference ...
... May 26 Results of clinical studies ... Staccato® loxapine (AZ-004) reduced agitation in patients, regardless of ... levels were observed as early as 10 minutes after ... by the Positive and Negative Syndrome Scale - Excited ...
Cached Medicine Technology:Tibotec Therapeutics Debuts Innovative Web Portal for HIV/AIDS Front-Line Service Providers 2Tibotec Therapeutics Debuts Innovative Web Portal for HIV/AIDS Front-Line Service Providers 3Tibotec Therapeutics Debuts Innovative Web Portal for HIV/AIDS Front-Line Service Providers 4Staccato(R) Loxapine (AZ-004) Reduced Signs and Symptoms of Agitation as Early as Ten Minutes After Dosing in Patients with Schizophrenia or Bipolar Disorder 2Staccato(R) Loxapine (AZ-004) Reduced Signs and Symptoms of Agitation as Early as Ten Minutes After Dosing in Patients with Schizophrenia or Bipolar Disorder 3Staccato(R) Loxapine (AZ-004) Reduced Signs and Symptoms of Agitation as Early as Ten Minutes After Dosing in Patients with Schizophrenia or Bipolar Disorder 4Staccato(R) Loxapine (AZ-004) Reduced Signs and Symptoms of Agitation as Early as Ten Minutes After Dosing in Patients with Schizophrenia or Bipolar Disorder 5Staccato(R) Loxapine (AZ-004) Reduced Signs and Symptoms of Agitation as Early as Ten Minutes After Dosing in Patients with Schizophrenia or Bipolar Disorder 6Staccato(R) Loxapine (AZ-004) Reduced Signs and Symptoms of Agitation as Early as Ten Minutes After Dosing in Patients with Schizophrenia or Bipolar Disorder 7Staccato(R) Loxapine (AZ-004) Reduced Signs and Symptoms of Agitation as Early as Ten Minutes After Dosing in Patients with Schizophrenia or Bipolar Disorder 8
(Date:8/28/2015)... ... August 28, 2015 , ... The Nashville Business Journal recently ... in business. Mr. Troy Mizell, Chairman of the Board at MyGenetx, is ... 2015 Veterans Awards will recognize Nashville military veterans who, through their professional and ...
(Date:8/28/2015)... , ... August 28, 2015 , ... Northridge dentists ... Zoom teeth whitening. For just $199, patients can currently receive a one hour treatment ... teeth whitening procedures, but it includes a number of unique features that can turn ...
(Date:8/28/2015)... Raleigh, NC (PRWEB) , ... August 28, 2015 , ... ... mesothelioma will not be available for general use any time soon, according to educational ... MTG-201, a biologic therapy that received orphan drug designation for mesothelioma last week from ...
(Date:8/28/2015)... MO (PRWEB) , ... August 28, 2015 , ... ... testosterone lawsuits now consolidated as MDL 2545, Testosterone Replacement Therapy Products ... a cap on the number of custodial files the PSC may receive for ...
(Date:8/28/2015)... ... August 28, 2015 , ... An independent ... result in high percentages of change to treatment recommendations and diagnosis. The 2015 ... at Tennessee Tech University and analyzed WorldCare’s second opinion process. , The study ...
Breaking Medicine News(10 mins):Health News:MyGenetx Board Member Receives Veterans Award 2Health News:Northridge Dentists Dr. Elyson and Dr. Assili Now Offer a Special Promotion on Zoom Teeth Whitening 2Health News:Surviving Mesothelioma Puts New Orphan Drug into Perspective in New Article 2Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 2Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 3Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 4Health News:WorldCare International, Inc. Celebrates Findings of Independent ROI Study 2
... do not get training posts through the flawed Medical ... the government// is stalling on a new contract for ... figures show that 34,250 doctors are chasing 18,500 specialist ... far given no commitment that trainee doctors will be ...
... promising anti-inflammatory drug failed to improve symptoms of moderate ... a large, multi-center trial. ,The results ... published in the first issue of the May American ... the American Thoracic Society. ,According to an ...
... a heart attack or severe chest pain today are much less ... even a few years ago, according to a new international study. ... a significant drop in the rate of heart failure and death ... ,The study finds that the change occurred at the same time ...
... war veterans who have come back after combat in the ... chemicals and other harmful substances, there is a decreased volume ... and memory. ,Roberta White, chair of the department ... Health, revealed, at the American Academy of Neurology's 59th Annual ...
... alert following a malaria epidemic that has claimed at ... ,"Doctors and paramedics have been put on alert ... out to vulnerable areas to check the spread of ... ,Eight of Assam's 29 districts have been ...
... immediately spot the victims of a bite from the Brazilian ... and an increase in blood pressure, they also sport an ... quest for more Viagras. Scientists say they have figured out ... boost. , “The erection is a side effect ...
Cached Medicine News:Health News:Junior Doctors Facing More Misery Because of Contract Deadlock: BMA 2Health News:Anti-inflammatory Drug Fails to Improve COPD Symptoms 2Health News:Good News for Sufferers of Heart Attack, Chest Pain 2Health News:Good News for Sufferers of Heart Attack, Chest Pain 3Health News:Good News for Sufferers of Heart Attack, Chest Pain 4Health News:Gulf War Veterans Exhibit Memory Impairment 2Health News:Malaria Claims 25 Lives in Assam 2Health News:Brazil Spider Offers Hope for Those Suffering from Erectile Dysfunction 2
Inquire...
Inquire...
Inquire...
The modular, high-end stereomicroscope; meets even the most critical demands in research and quality control provides high-contrast images with excellent depth of field and color fidelity...
Medicine Products: